John A. Thompson, MD

John A. Thompson, MD

Director, Phase 1 Medical Oncology
Department of Medicine
Division of Oncology

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Ave E, CE2-128
Seattle, WA 98109-1023

Admin Contact

Carly Zipper

Specialty / Expertise

Melanoma and Renal Cancer

Research Interests

  • Director, Phase 1 Clinical Trials Program, UW/FHCRC
  • Immunotherapy
  • Activated lymphocytes and cytokines

Current Research Projects

A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety to Assess the Safety and Pharmacokinetics of Recombinant Interleukin 21 (rIL-21) Administered Concomitantly with Sorafenib (Nexavar) in Subjects with Metastatic Renal Cell Carcinoma.
Role: PI

Phase 3b, Randomized, Open-Label Study of Bevacizumab (Avastin) + Temsirolimus (Torisel) vs. Bevacizumab (Avastin) + Interferon-Alfa (Roferon) as First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma.
Role: PI

A randomized, open label, multi-center phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for first-line treatment of patients with metastatic clear cell carcinoma of the kidney.
Role: PI

A double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of recMAGE-A3 + AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma.
Role: PI

Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and /or Metastatic Renal Cell Carcinoma.
Role: PI

An open-label, dose escalation, Phase I study of MLN9708, a second generation proteasome inhibitor, in adult patients with advanced non-hematologic malignancies.
Role: PI

A Phase I, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-75 in patients with relapsed or refractory CD70-positive non-Hodgkin Lymphoma or renal cell carcinoma.
Role: PI

A multi-center, open-label, dose-escalation study to assess the pharmacokinetics of intravenous ASA404 in adult advanced cancer patients with impaired renal function and with normal renal function.
Role: PI

A Phase II Study to Evaluate the Relationship between IMC-1121B Therapy and Corrected QT (QTc) Interval Changes in Patients with Advanced Cancer
Role: PI

A Phase Ib/II Study of ALT-801 with Cisplatin in Patient with Metastatic Melanoma.
Role: PI

A Phase 1, Open-label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M8F Monotherapy in Subjects with Advanced Renal Cell Carcinoma
Role: PI

A Phase 1, Open-Label, Dose Escalation Study of ASG-5ME in Subjects with Pancreatic Adenocarcinoma
Role: PI

A Phase 1b Study of LY573636-sodium in Combination with Sunitinib Malate (Sutent) in Patients with Metastatic Renal Cell Cancer
Role: PI


Dr. Thompson received his MD from University of Alabama, Birmingham, AL. He completed his Internal Medicine Residency at the University of Washington, Seattle, WA. He was a Post-Doctoral Fellow in Oncology at the University of Washington, Seattle, WA.

Selected Publications

Thompson, J.A., Lee, D.J., Cox, W.W., Lindgren, C.G., Collins, C., Neraas, K.A., Dennin, R.A., and Fefer, A.:  Recombinant interleukin-2:  Toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial.  Cancer Res.  47:4202-4207, 1987.

Thompson, J.A., Lee, D.J., Lindgren, C.G., Benz, L.A., Collins, C., Levitt, D.J., and Fefer, A.:  Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.  J. Clin. Oncol.  6:669-678, 1988.
Thompson, J.A., Lee, D.J., Lindgren, C.G., Benz, L.A., Collins, C., Shuman, W.P., Levitt, D.J., and Fefer, A.:  Influence of schedule of interleukin-2 administration on therapy with interleukin-2 and lymphokine-activated killer cells.  Cancer Research  49:235-240, 1989.

Thompson, J.A., Shulman, K.L., Benyunes, M.C., Collins, C., Lange, P.H., Bush, W.H., Lindgren, C.L., Benz, L.A., & Fefer, A.:  Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma.  J. Clin. Oncol.  10:960-968, 1992.
Thompson, J.A., Bianco, J.A., Benyunes, M.C., Neubauer, M., Slattery, J.T., and Fefer, A.:  Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma.  Cancer Res.  54:3436-41, 1994.
Figlin, R.A., Thompson, J.A., Bukowski, R.M., Vogelzang, N.J., Novick, A.C., Lange, P., Steinberg, G., and Belldegrun, A.S. Multicenter, randomized, phase II/III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma, J. Clin. Oncol., 17:2521-2529,  1999.
Thompson, J.A., Gilliland, D.G., Prchal, J.T., Bennett, J.M., Larholt, K., Nelson, R.A., Rose, E.H., Dugan, M.H., and the GM/EPO MDS Study Group. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood 95:1175-1179, 2000.
Yee, C., Thompson, J.A., Byrd, D., Riddell, S.R., Roche, P., Cellis, E., and Greenberg, P.D. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells Proc Natl Acad Sci USA 99(25):16168-73, 2002.
Thompson, J.A., Figlin, R.A., Sifri-Steele, C., Berenson, R.J., and Frohlich, M.W. A Phase I trial of CD3/CD28 activated T cells (Xcellerated T cellsTM) and IL-2 in patients with metastatic renal cell carcinoma. Clin Cancer Res 9:3562-3560, 2003

Mitchell, M.S., Abrams, J., Thompson, J.A., et al  Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b for resected stage III cutaneous melanoma. J Clin Oncol 25:2078-2085, 2007

Thompson, J.A., Curti, B.D., Redman, B.G., Bhatia, S., Weber, J.S., Agarwala, S.S., Sievers, E.L., Hughes, S.D. DeVries, T.A., and Hausman, D.F. Phase 1 study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol, 26:2034-2039, 2008.

Thompson, J.A., Fisher, R.I., LeBlanc, M., Forman, S.J., Press, O.W., Unger, J.M., Nademanee, A.P., Stiff, P.J., Petersdorf, S.H., Fefer, A. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem cell transplantation followed by randomization to therapy with Interleukin-2 versus observation for patients with non-Hodgkin’s lymphoma: Results of a Phase III randomized trial by the Southwest Oncology Group (SWOG 9438). Blood 111:4048-4054, 2008.

Hunder, N., Wallen, H., Cao, J., Hendricks, D., Reilly, J.Z., Rodmyre, R., Jungbluth, A., Gnjatic, S.,  Thompson, J.A.,  and Yee, C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358:2698-2703, 2008.

Thompson, J. A., Kuzel, T., Drucker, B. J., Urba, W.J., and Bukowski, R.M., Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter Phase I/II study. Clinical Genitourinary Cancer, 7 (3): E58-E65, 2009.

Weber, J., Thompson, J.A., Hamid, O., Minor, D., Amin, A., Ron, I., Ridolfi, R., Assi, H., Maraveyas, A., Berman, D., Siegel, J., O’Day, S.J. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Can Research 15(17):5591-5598, 2009.

Last updated: May 2011